Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the current study is to evaluate the ability of Eylea to induce a regression
of PED height on patients previously extensively treated by Lucentis.
The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval
injection until week 26.